Pharmaroth Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Pharmaroth Labs
ROTH Stock  USD 0.0001  0.00  0.00%   
Pharmaroth Labs' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Pharmaroth Labs' valuation are provided below:
Gross Profit
80.5 K
Profit Margin
(2.79)
Market Capitalization
14.9 K
Enterprise Value Revenue
7.0886
Revenue
200.2 K
We have found one hundred eleven available trending fundamental ratios for Pharmaroth Labs, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Pharmaroth Labs recent fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The Pharmaroth Labs' current Market Cap is estimated to increase to about 2.1 M. The Pharmaroth Labs' current Enterprise Value is estimated to increase to about 2.2 M

Pharmaroth Labs Total Revenue

219,237

Check Pharmaroth Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharmaroth Labs' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 154.1 K or Total Revenue of 219.2 K, as well as many indicators such as Price To Sales Ratio of 10.56, Dividend Yield of 0.0 or Days Sales Outstanding of 193. Pharmaroth financial statements analysis is a perfect complement when working with Pharmaroth Labs Valuation or Volatility modules.
  
Build AI portfolio with Pharmaroth Stock
Check out the analysis of Pharmaroth Labs Correlation against competitors.
For more detail on how to invest in Pharmaroth Stock please use our How to Invest in Pharmaroth Labs guide.

Pharmaroth Labs Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets367.1 K349.7 K263.6 K
Slightly volatile
Total Current Liabilities1 M992.8 K772.1 K
Slightly volatile
Cash9931 K2.3 K
Slightly volatile
Short Term Investments400450491
Slightly volatile
Other Current Assets64.3 K80.2 K70 K
Pretty Stable
Total Liabilities1 M981.6 K762.6 K
Slightly volatile
Total Current Assets367.1 K349.7 K263.6 K
Slightly volatile
Common Stock471.7 K449.3 K364.1 K
Slightly volatile
Long Term Debt345.7 K329.2 K275.4 K
Slightly volatile
Short and Long Term Debt345.7 K329.2 K275.4 K
Slightly volatile
Short Term Debt345.7 K329.2 K275.4 K
Slightly volatile
Accounts Payable740.6 K705.3 K532.7 K
Slightly volatile
Other Current Liabilities200 K225 K245.3 K
Slightly volatile
Net Receivables69.9 K95.1 K77.9 K
Pretty Stable
Inventory109 K173 K113.3 K
Slightly volatile

Pharmaroth Labs Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative154.1 K188.8 K224.7 K
Slightly volatile

Pharmaroth Labs Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock19.7 K20.7 K25.6 K
Slightly volatile
Net Borrowings28.7 K27.3 K23.4 K
Slightly volatile
Total Cash From Financing Activities31.6 K20.7 K26.3 K
Slightly volatile
Change To Netincome6 K6.3 K70.6 K
Slightly volatile
Change To Liabilities197.8 K188.4 K114.3 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.567.228.3026
Slightly volatile
Days Sales Outstanding193191180
Pretty Stable
Capex To Depreciation374420458
Slightly volatile
EV To Sales11.078.89.1756
Slightly volatile
Inventory Turnover0.790.832.5679
Slightly volatile
Days Of Inventory On Hand476454354
Slightly volatile
Payables Turnover1.011.061.4975
Slightly volatile
Average Inventory39.3 K66.1 K58.7 K
Slightly volatile
Capex To Revenue0.40.370.3546
Slightly volatile
Cash Per Share0.00.00.0
Slightly volatile
Days Payables Outstanding184357314
Slightly volatile
Income Quality0.40.220.3007
Slightly volatile
ROE0.180.190.5882
Slightly volatile
Current Ratio0.20.320.3104
Slightly volatile
Receivables Turnover2.691.982.5057
Very volatile
Capex Per Share4.0E-43.0E-44.0E-4
Slightly volatile
Average Receivables98.6 K62.1 K79.6 K
Slightly volatile
Revenue Per Share9.0E-45.0E-46.0E-4
Pretty Stable
Interest Debt Per Share7.0E-48.0E-40.001
Slightly volatile
Debt To Assets1.120.950.994
Slightly volatile
Operating Cycle320603510
Slightly volatile
Days Of Payables Outstanding184357314
Slightly volatile
Return On Capital Employed0.150.16370.5805
Slightly volatile
Quick Ratio0.140.160.1899
Pretty Stable
Net Income Per E B T1.091.151.8088
Slightly volatile
Cash Ratio0.00150.00150.0042
Slightly volatile
Days Of Inventory Outstanding476454354
Slightly volatile
Days Of Sales Outstanding193191180
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.11.151.0156
Slightly volatile
Fixed Asset Turnover184207225
Slightly volatile
Debt Ratio1.120.950.994
Slightly volatile
Price Sales Ratio10.567.228.3026
Slightly volatile
Asset Turnover1.110.690.8099
Slightly volatile
Gross Profit Margin0.310.360.3659
Slightly volatile
Return On Equity0.180.190.5882
Slightly volatile

Pharmaroth Labs Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.1 M1.3 M1.5 M
Slightly volatile
Enterprise Value2.2 M1.6 M1.7 M
Slightly volatile

About Pharmaroth Labs Financial Statements

Investors use fundamental indicators, such as Pharmaroth Labs' revenue or net income, to determine how well the company is positioned to perform in the future. Although Pharmaroth Labs' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Total Revenue208.8 K219.2 K
Cost Of Revenue125.3 K131.5 K
Capex To Revenue 0.37  0.40 
Ebit Per Revenue(0.45)(0.48)

Currently Active Assets on Macroaxis

DDDupont De Nemours
CRDOCredo Technology Group
GOOGAlphabet Inc Class C
BACBank of America
CRMSalesforce
When determining whether Pharmaroth Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pharmaroth Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmaroth Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmaroth Labs Stock:
How To Invest In Pharmaroth
Details
Is Pharmaroth Stock a good investment?
Details
What is Pharmaroth Labs' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Healthcare Companies
View
Check out the analysis of Pharmaroth Labs Correlation against competitors.
For more detail on how to invest in Pharmaroth Stock please use our How to Invest in Pharmaroth Labs guide.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmaroth Labs. If investors know Pharmaroth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pharmaroth Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
0.002
The market value of Pharmaroth Labs is measured differently than its book value, which is the value of Pharmaroth that is recorded on the company's balance sheet. Investors also form their own opinion of Pharmaroth Labs' value that differs from its market value or its book value, called intrinsic value, which is Pharmaroth Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pharmaroth Labs' market value can be influenced by many factors that don't directly affect Pharmaroth Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Pharmaroth Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharmaroth Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharmaroth Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY